166 related articles for article (PubMed ID: 31266785)
1. MERTK Acts as a Costimulatory Receptor on Human CD8
Peeters MJW; Dulkeviciute D; Draghi A; Ritter C; Rahbech A; Skadborg SK; Seremet T; Carnaz Simões AM; Martinenaite E; Halldórsdóttir HR; Andersen MH; Olofsson GH; Svane IM; Rasmussen LJ; Met Ö; Becker JC; Donia M; Desler C; Thor Straten P
Cancer Immunol Res; 2019 Sep; 7(9):1472-1484. PubMed ID: 31266785
[TBL] [Abstract][Full Text] [Related]
2. Expression of TAM-R in Human Immune Cells and Unique Regulatory Function of MerTK in IL-10 Production by Tolerogenic DC.
Giroud P; Renaudineau S; Gudefin L; Calcei A; Menguy T; Rozan C; Mizrahi J; Caux C; Duong V; Valladeau-Guilemond J
Front Immunol; 2020; 11():564133. PubMed ID: 33101282
[TBL] [Abstract][Full Text] [Related]
3. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
[TBL] [Abstract][Full Text] [Related]
4. Multifaceted Role of BTLA in the Control of CD8
Ritthipichai K; Haymaker CL; Martinez M; Aschenbrenner A; Yi X; Zhang M; Kale C; Vence LM; Roszik J; Hailemichael Y; Overwijk WW; Varadarajan N; Nurieva R; Radvanyi LG; Hwu P; Bernatchez C
Clin Cancer Res; 2017 Oct; 23(20):6151-6164. PubMed ID: 28754817
[No Abstract] [Full Text] [Related]
5. IL-9 promotes the survival and function of human melanoma-infiltrating CD4(+) CD8(+) double-positive T cells.
Parrot T; Allard M; Oger R; Benlalam H; Raingeard de la Blétière D; Coutolleau A; Preisser L; Desfrançois J; Khammari A; Dréno B; Labarrière N; Delneste Y; Guardiola P; Gervois N
Eur J Immunol; 2016 Jul; 46(7):1770-82. PubMed ID: 27094152
[TBL] [Abstract][Full Text] [Related]
6. TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting.
Peeters MJW; Rahbech A; Thor Straten P
Cancer Immunol Immunother; 2020 Feb; 69(2):237-244. PubMed ID: 31664482
[TBL] [Abstract][Full Text] [Related]
7. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
8. MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.
Cook RS; Jacobsen KM; Wofford AM; DeRyckere D; Stanford J; Prieto AL; Redente E; Sandahl M; Hunter DM; Strunk KE; Graham DK; Earp HS
J Clin Invest; 2013 Aug; 123(8):3231-42. PubMed ID: 23867499
[TBL] [Abstract][Full Text] [Related]
9. MERTK tyrosine kinase receptor together with TIM4 phosphatidylserine receptor mediates distinct signal transduction pathways for efferocytosis and cell proliferation.
Nishi C; Yanagihashi Y; Segawa K; Nagata S
J Biol Chem; 2019 May; 294(18):7221-7230. PubMed ID: 30846565
[TBL] [Abstract][Full Text] [Related]
10. TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells.
Ahmadzadeh M; Rosenberg SA
J Immunol; 2005 May; 174(9):5215-23. PubMed ID: 15843517
[TBL] [Abstract][Full Text] [Related]
11. The Emerging Role of CD8
Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
Front Immunol; 2018; 9():1904. PubMed ID: 30158938
[TBL] [Abstract][Full Text] [Related]
12. MERTK as negative regulator of human T cell activation.
Cabezón R; Carrera-Silva EA; Flórez-Grau G; Errasti AE; Calderón-Gómez E; Lozano JJ; España C; Ricart E; Panés J; Rothlin CV; Benítez-Ribas D
J Leukoc Biol; 2015 Apr; 97(4):751-60. PubMed ID: 25624460
[TBL] [Abstract][Full Text] [Related]
13. Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity.
Prins RM; Incardona F; Lau R; Lee P; Claus S; Zhang W; Black KL; Wheeler CJ
J Immunol; 2004 Feb; 172(3):1602-11. PubMed ID: 14734741
[TBL] [Abstract][Full Text] [Related]
14. CD58/CD2 Is the Primary Costimulatory Pathway in Human CD28-CD8+ T Cells.
Leitner J; Herndler-Brandstetter D; Zlabinger GJ; Grubeck-Loebenstein B; Steinberger P
J Immunol; 2015 Jul; 195(2):477-87. PubMed ID: 26041540
[TBL] [Abstract][Full Text] [Related]
15. Naive CD8+ T cells do not require costimulation for proliferation and differentiation into cytotoxic effector cells.
Wang B; Maile R; Greenwood R; Collins EJ; Frelinger JA
J Immunol; 2000 Feb; 164(3):1216-22. PubMed ID: 10640733
[TBL] [Abstract][Full Text] [Related]
16. Myeloid cell-derived PROS1 inhibits tumor metastasis by regulating inflammatory and immune responses via IL-10.
Maimon A; Levi-Yahid V; Ben-Meir K; Halpern A; Talmi Z; Priya S; Mizraji G; Mistriel-Zerbib S; Berger M; Baniyash M; Loges S; Burstyn-Cohen T
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33848267
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-155 Expression Is Enhanced by T-cell Receptor Stimulation Strength and Correlates with Improved Tumor Control in Melanoma.
Martinez-Usatorre A; Sempere LF; Carmona SJ; Carretero-Iglesia L; Monnot G; Speiser DE; Rufer N; Donda A; Zehn D; Jandus C; Romero P
Cancer Immunol Res; 2019 Jun; 7(6):1013-1024. PubMed ID: 31043416
[TBL] [Abstract][Full Text] [Related]
18. Marked anti-tumor effects of CD8(+)CD62L(+) T cells from melanoma-bearing mice.
Liao Y; Geng P; Tian Y; Miao H; Liang H; Zeng R; Ni B; Ruan Z
Immunol Invest; 2015; 44(2):147-63. PubMed ID: 25122543
[TBL] [Abstract][Full Text] [Related]
19. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
Lee-Sherick AB; Jacobsen KM; Henry CJ; Huey MG; Parker RE; Page LS; Hill AA; Wang X; Frye SV; Earp HS; Jordan CT; DeRyckere D; Graham DK
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385715
[TBL] [Abstract][Full Text] [Related]
20. Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function.
Koneru M; Schaer D; Monu N; Ayala A; Frey AB
J Immunol; 2005 Feb; 174(4):1830-40. PubMed ID: 15699109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
